Moderna
Last updated Jun 24, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
75%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Vaccine
- Oncology
- Non-small Cell Lung Cancer
- HPV-related cancers
Highest priority development: FDA Approves First Generics of Gilotrif (afatinib) Tablets
Regulatory precedent
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Moderna.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 75%
Active Signals
5
Investigate Priority
2
Opportunity Score
187
Buyer Quality
9 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 24, 2026Score 44Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Oncology · Non-small Cell Lung Cancer
- InvestigateJun 17, 2026Score 37E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice
Oncology · HPV-related cancers
- InvestigateJun 16, 2026Score 37NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273
Infectious Disease · COVID-19
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA Approves First Generics of Gilotrif (afatinib) TabletsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumorsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical DevelopmentModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Drug Trials SnapshotsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 37E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice
Oncology · HPV-related cancers
- InvestigateScore 37NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273
Infectious Disease · COVID-19
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Moderna right now?
- Which regulatory precedents should Moderna monitor in Infectious Disease and Vaccine?
- Which pipeline programs should Moderna prioritize for competitive review?
- What signals require immediate investigation for Moderna?
- Summarize the strategic implications of recent developments for Moderna.
- Where is the greatest uncertainty in Moderna's competitive positioning?